ARTICLE | Clinical News
Prometic's Ryplazim gets rare pediatric disease designation
September 1, 2017 3:16 PM UTC
Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA granted rare pediatric disease designation to Ryplazim to treat congenital plasminogen deficiency. The human plasma-derived plasminogen also has Orphan Drug and Fast Track designations from FDA...
BCIQ Company Profiles